Long COVID prevalence high in Scandinavians with severe COVID-19

A collaborative study involving researchers from Karolinska Institutet has charted the prevalence of severe physical symptom burden amongst Scandinavians for up to two years after a SARS-CoV-2 infection.

RedShiftBio launches Aurora TX: Revolutionizing RNA and protein analysis with ultra-sensitive microfluidic modulation spectroscopy and thermal ramping capability

RedShiftBio, a leader in innovative biophysical characterization and bioprocess analytical solutions, proudly announces the launch of Aurora TX at The Protein & Antibody Engineering Summit (PEGS), kicking

May 16, 2024

Q&A: How the FDA is approaching AI in clinical trials and drug development

In the last year, pharma incumbents have leaned into partnerships with AI-driven startups to supercharge drug discovery efforts. High-powered models of protein structure and molecule

October 9, 2024

Takeda to pay $200M for rights to anemia drug from Keros

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.